Aurinia Pharmaceuticals Inc. (AUPH) KPIs and segments
Close on Nov 13, 2026Market cap $2.11BP/E 6.9Yield –
KPIs & segments
Operating metrics and segments that drive Aurinia Pharmaceuticals's business
Aurinia Pharmaceuticals's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net product sales($M) | 79.4 | 79.4 | 73.6 | 74.2 | 70.6 | 66.6 | 60.0 | 57.6 | 55.5 | 55.0 | 48.1 | 42.3 | |
License, collaboration and royalty revenue($M) | 4.28 | 3.81 | 4.14 | 2.94 | 2.84 | 3.43 | 2.49 | 2.29 | 12.3 | 2.16 | 2.23 | ||
1 metric has no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-10-30.
See a number that looks wrong?